Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease.

Neumann U, Ufer M, Jacobson LH, Rouzade-Dominguez ML, Huledal G, Kolly C, Lüönd RM, Machauer R, Veenstra SJ, Hurth K, Rueeger H, Tintelnot-Blomley M, Staufenbiel M, Shimshek DR, Perrot L, Frieauff W, Dubost V, Schiller H, Vogg B, Beltz K, Avrameas A, Kretz S, Pezous N, Rondeau JM, Beckmann N, Hartmann A, Vormfelde S, David OJ, Galli B, Ramos R, Graf A, Lopez Lopez C.

EMBO Mol Med. 2018 Sep 17. pii: e9316. doi: 10.15252/emmm.201809316. [Epub ahead of print]

2.

Inhibition of Escherichia coli porphobilinogen synthase using analogs of postulated intermediates.

Jarret C, Stauffer F, Henz ME, Marty M, Lüönd RM, Bobálová J, Schürmann P, Neier R.

Chem Biol. 2000 Mar;7(3):185-96.

3.
4.

On the formation of the mixed pyrrole catalysed by porphobilinogen synthase from Rhodobacter spheroides.

Lüönd RM, Neier R.

Biochim Biophys Acta. 1996 Feb 9;1289(1):83-6.

PMID:
8605237
5.

A direct link between LY83583, a selective repressor of cyclic GMP formation, and glutathione metabolism.

Lüönd RM, McKie JH, Douglas KT.

Biochem Pharmacol. 1993 Jun 22;45(12):2547-9.

PMID:
8101080

Supplemental Content

Loading ...
Support Center